oxfordjournals.org[HTML]MJ Post, R Laham, FW Sellke, … - …, 2001 - … .cardiovascres.oxfordjournals.org Therapeutic angiogenesis in cardiovascular disease aims at improving myocardial function by
increasing blood flow to ischemic myocardium that is not amenable to traditional forms of
revascularization. Preclinical data have provided proof of the concept that angiogenic ... Cited by 140 - Related articles - All 9 versions
aspetjournals.org[HTML]RJ Laham, M Rezaee, M Post, FW Sellke, RA … - Drug Metabolism and …, 1999 - ASPET Therapeutic angiogenesis using various heparin-binding growth factors is a promising treatment
for ischemic heart disease. Single dose intracoronary (IC) or iv delivery are most practical for
clinical use. This study was designed to investigate the myocardial and tissue deposition ... Cited by 83 - Related articles - BL Direct - All 9 versions
M Ruel, RJ Laham, JA Parker, MJ Post, JA … - The Journal of …, 2002 - AATS/WTSA This work was funded in part by National Institutes of Health grants HL-53793 and HL-56993
(Dr Simons), HL-46716 (Dr Sellke), HL-63609 (Dr Laham), and M01-RR0132 (Dr Laham). Dr
Ruel is supported by research fellowship awards from the Heart and Stroke Foundation of ... Cited by 111 - Related articles - BL Direct - All 7 versions
ahajournals.org[HTML]M Simons, RO Bonow, NA Chronos, DJ Cohen, FJ … - Circulation, 2000 - Am Heart Assoc From the Angiogenesis Research Center (MS, RJL, FWS), Interventional Cardiology (DJC,
RJL) and Division of Cardiothoracic Surgery (FWS), BIDMC, Harvard Medical School,
Boston, Mass; Division of Cardiology, Northwestern University School of Medicine (ROB), ... Cited by 362 - Related articles - All 4 versions
ahajournals.org[HTML]M Simons, BH Annex, RJ Laham, N Kleiman, T Henry … - Circulation, 2002 - Am Heart Assoc Methods and Results— FIRST is a multicenter, randomized, double-blind, placebo-controlled
trial of a single intracoronary infusion of rFGF2 at 0, 0.3, 3, or 30 µg/kg (n=337 patients). Efficacy
was evaluated at 90 and 180 days by exercise tolerance test, myocardial nuclear ... Cited by 365 - Related articles - BL Direct - All 15 versions
oxfordjournals.org[HTML]DF Lazarous, M Shou, JA Stiber … - Cardiovascular …, 1997 - cardiovascres.oxfordjournals.org Objective: We have shown that basic fibroblast growth factor (bFGF/FGF-2) enhances myocardial
collateral development in a canine model of progressive coronary occlusion when delivered
via the left atrial or intracoronary routes; however, we have found intravenous bFGF ... Cited by 121 - Related articles - All 11 versions
R Khurana, M Simons - Trends in Cardiovascular Medicine, 2003 - Elsevier The aim of therapeutic angiogenesis in cardiovascular disease states is to improve myocardial
and peripheral extremity perfusion and function within ischemic regions that are not amenable
to traditional modes of revascularization. Substantial “proof of concept,” efficacy, and ... Cited by 47 - Related articles - All 5 versions
ahajournals.org[HTML]RJ Laham, FW Sellke, ER Edelman, JD Pearlman, JA … - Circulation, 1999 - Am Heart Assoc Methods and Results—We conducted a randomized, double-blind, placebo-controlled study
of basic fibroblast growth factor (bFGF; 10 or 100 µg versus placebo) delivered via
sustained-release heparin-alginate microcapsules implanted in ischemic and viable but ... Cited by 342 - Related articles - BL Direct - All 8 versions
angiogenesis-center.org[PDF]K Sato, RJ Laham, JD Pearlman, D … - The Annals of …, 2000 - Soc Thorac Surgeons Methods. Using a pig model of chronic myocardial ischemia, we evaluated the efficacy of intravenous
and intracoronary infusion of FGF-2 at 2 and 6 µg/kg compared with a vehicle control. Improvement
in myocardial perfusion and function was assessed by angiography, colored ... Cited by 65 - Related articles - All 9 versions
EF Unger, L Goncalves, SE Epstein, EY Chew, … - The American journal of …, 2000 - Elsevier We sought to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of basic
fibroblast growth factor (bFGF), administered as a single intracoronary injection, to subjects with
stable angina pectoris secondary to coronary artery disease. bFGF, an angiogenic growth ... Cited by 94 - Related articles - BL Direct - All 4 versions
